Anmeldung erfolgt in Kürze...
Details werden geladen...
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | The Manila Times
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
Ähnliche Seiten
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-business-update/2399379Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/07/tmt-newswire/globenewswire/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-updates/2400922Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/climb-bio-reports-second-quarter-2026-financial-results-and-provides-business-updates/2399893CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/cg-oncology-reports-second-quarter-2026-financial-results-and-provides-business-updates/2400069Immunocore reports second quarter financial results and provides a business update | The Manila Times
https://www.manilatimes.net/2026/08/06/tmt-newswire/globenewswire/immunocore-reports-second-quarter-financial-results-and-provides-a-business-update/2399911